← Research library

Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus

Observational study · 2007

What was studied
Type-1 diabetes patients receiving adjunctive care
Main finding
Adjunctive Vilon in type 1 diabetes was associated with immune and coagulation-marker changes, including antithrombin III, protein C and fibrinolysis. No autoimmune disease-modifying effect is established.

Reported findings and study design

Population or model Type-1 diabetes patients receiving adjunctive care

Results · Primary indexed abstract, PMID 18306698.
MeasureResultComparison, timing and statistics
Immune and coagulation markersReported changes during adjunctive Vilon treatment; numerical effect sizes not supplied

Type 1 diabetes report, not proof of beta-cell preservation, restored tolerance or replacement of insulin. Possible overlap with the 2006 publication prevents pooling.

Source for these results ↗ · Reviewed 2026-11-05

Study limitations and source details

Study limitations

  • The abstract leaves enrollment and allocation unclear. Its findings cannot establish an alternative to insulin.
  • Full methods, adverse-event reporting and independent replication remain to be appraised.

Source details

Journal publication

Europe PMC indexed citation and abstract checked. Full original paper not reviewed.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus Advances in gerontology = Uspekhi gerontologii 20(2):106-115. PMID 18306698

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards